LOS ALTOS, Calif.–(BUSINESS WIRE)–HeartVista, a pioneer in AI-assisted MRI solutions, announced the formation of its Medical and Scientific Advisory Board, including notable thought leaders from Stanford University and the University of Wisconsin. “The past year was an inflection point for HeartVista, which was full of significant milestones as we received […]
Financial
Endologix Reports Fourth Quarter and Fiscal Year 2019 Financial Results
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2019. Global revenue in the fourth quarter of 2019 was $35.8 million, a 3.0% increase from $34.7 million […]
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted Gencaro PRECISION-AF clinical trial initiation anticipated fourth quarter of 2020 Trial to evaluate Gencaro as a potential treatment for prevention of atrial fibrillation in a heart failure population for which there are no […]
AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results
2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year 2019 International revenue of $45.0 million – an increase of 13.9% year over year MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading […]
Medtronic Reports Third Quarter Financial Results
Revenue of $7.7 Billion Increased 2.3% Reported and 2.6% Organic GAAP Diluted EPS of $1.42 Increased 51%; Non-GAAP Diluted EPS of $1.44 Increased 12% Cash Flow from Operations of $2.4 Billion Increased 17%; Free Cash Flow of $2.1 Billion Increased 21% Company Raises Full Year EPS Guidance DUBLIN, Feb. 18, […]
Gore Named a Fortune 100 Best Company to Work For®
NEWARK, Del., Feb. 18, 2020 /PRNewswire/ — W. L. Gore & Associates — a materials science company known for its innovative products and work environment — earned a spot on the 2020 Fortune 100 Best Companies to Work For® list, announced today. This marks Gore’s 21st appearance since the rankings debuted in 1998. […]
Biotricity Posts Calendar Q4 Results that Show Continued Growth
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced calendar fourth quarter financial results for the three months which ended December 31, 2019. FOURTH QUARTER HIGHLIGHTS Revenues for the three months which ended December 31, 2019 grew by 225% […]
BioVentrix Announces Gregg Stone, MD, as Co-Principal Investigator for ALIVE Pivotal Trial of Transcatheter Device for Heart Failure
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced that Gregg Stone, MD, of New York’s Mount Sinai Health System has signed on to the pivotal ALIVE Trial of the Revivent TC™ TransCatheter Ventricular Enhancement System as co-principal investigator. Dr. Stone […]
Shockwave Medical Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Financial Outlook
SANTA CLARA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) — Shockwave Medical Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2019. Recent Highlights Recognized revenue of $14.3 […]
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020
LAVAL, Québec, Feb. 14, 2020 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG) (triglyceride blood levels from 500 mg/dL […]



